Generic Pharmaceuticals Global Markets Report 2022: Focus on CNS; Cardiovascular; Dermatology; Genitourinary/Hormonal; Respiratory; Rheumatology; Diabetes; Oncology – ResearchAndMarkets.com
BioTech 365
JUNE 16, 2022
Generic Pharmaceutical Related Topics 
40 
Global Life Science Filtration Market Forecast to 2028 – Demand for Generic Pharmaceuticals Presents Opportunities – ResearchAndMarkets.com
BioTech 365
MARCH 30, 2022
Global Life Science Filtration Market Forecast to 2028 – Demand for Generic Pharmaceuticals Presents Opportunities – ResearchAndMarkets.com Global Life Science Filtration Market Forecast to 2028 – Demand for Generic Pharmaceuticals Presents Opportunities – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Life Science Filtration Global … Continue reading → Business Wire
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Global Generic Pharmaceutical Partnering Terms and Agreements Analysis Report 2010-2020 – ResearchAndMarkets.com
BioTech 365
SEPTEMBER 17, 2020
DUBLIN–(BUSINESS WIRE)–The “Global Generic Pharmaceutical Partnering Terms and Agreements 2010-2020” report has been added to ResearchAndMarkets.com’s offering. Global Generic Pharmaceutical Partnering Terms and Agreements 2010 to 2020 report provides a detailed understanding and analysis of how and why companies enter … Continue reading → Business Wire
AvKARE Recall: Erectile Dysfunction Drug and Antidepressant Mistakenly Packaged Together
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle.
AvKARE Recall: Erectile Dysfunction Drug and Antidepressant Mistakenly Packaged Together
XTalks
DECEMBER 14, 2020
AvKARE, a generics pharmaceutical manufacturer based in Pulaski, Tennessee, has issued a recall on one lot each of its sildenafil 100 mg tablets and trazodone 100 mg tablets due to a packaging “mix-up” in which both drugs were filled into the same bottle.
Most prolific drug patent challengers
Drug Patent Watch
JULY 26, 2022
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2017 to 2022. Companies that successfully challenge patents on branded drugs are granted six….
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 9, 2021
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six….
Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V.
BioTech 365
MARCH 12, 2021
Amring Pharmaceuticals Inc. Amring Pharmaceuticals Inc. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. Amring), a niche brand and generic pharmaceutical company, announced today an … Continue reading → Business Wire
Most prolific drug patent challengers
Drug Patent Watch
JULY 26, 2021
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2016 to 2021. Companies that successfully challenge patents on branded drugs are granted six….
Amring Pharmaceuticals Inc. Acquires LYSTEDA®
BioTech 365
DECEMBER 2, 2020
Amring Pharmaceuticals Inc. Acquires LYSTEDA® Amring Pharmaceuticals Inc. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. Amring), a generic pharmaceutical company, announced entering into an agreement with Ferring International Center S.A.
SOHM, Inc., Receives a Mandate for Development, Manufacturing, and Supply Two New topical products.
BioTech 365
AUGUST 4, 2021
the “Company”) (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic … Continue reading → EQS NewsfeedChino Hills, 08/04/2021 / 15:52, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc.
SOHM RECEIVES SEMI-ANNUAL ORDER FROM PRIVATE LABEL CUSTOMER TO BOOST ANTICIPATED REVENUE FOR 2021
BioTech 365
JUNE 3, 2021
the “Company”) (OTC PINK:SHMN), generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs … Continue reading → EQS NewsfeedChino Hills, 06/03/2021 / 18:51, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / June 3, 2021 / SOHM, Inc.
SOHM, Inc. Announce Company outlook for the year 2021 – Shareholder updates.
BioTech 365
MAY 18, 2021
OTC PINK:SHMN), a generic pharmaceutical, nutraceutical, and cosmeceutical company that manufactures and markets generic drugs covering … Continue reading → EQS NewsfeedChino Hills, 05/18/2021 / 15:31, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / May 18, 2021 / SOHM, Inc.
|
Teligent, Inc. Announces Third Quarter 2020 Results
BioTech 365
DECEMBER 31, 2020
NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the … Continue reading → GlobeNewswireTeligent, Inc. Announces Third Quarter 2020 Results Teligent, Inc. Announces Third Quarter 2020 Results BUENA, N.J., 31, 2020 (GLOBE NEWSWIRE) — Teligent, Inc.
Teligent Announces Completion of Series D Convertible Note Exchange
BioTech 365
SEPTEMBER 23, 2020
NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, announced the closing of the issuance of approximately $27.5 BUENA, N.J., 23, 2020 (GLOBE NEWSWIRE) — Teligent, Inc. million aggregate principal amount of Zero Coupon Convertible Senior Notes … Continue reading → GlobeNewswire
Most prolific drug patent challengers
Drug Patent Watch
NOVEMBER 8, 2020
This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2015 to 2020. Companies that successfully challenge patents on branded drugs are granted six…. The post Most prolific drug patent challengers appeared first on DrugPatentWatch - Make Better Decisions. Infographic
Current and future players in the osteoarthritis market
Pharmaceutical Technology
JULY 28, 2022
The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants and intra-articular (IA) injections.
Why Generic Medicines Are Especially Good for the U.S. Right Now
Drug Channels
SEPTEMBER 10, 2020
Today’s guest post comes from George Keefe, Senior Vice President of External Affairs and Public Policy at Teva Pharmaceuticals. George examines the economic impact of generic pharmaceuticals on the U.S.
Lannett To Report Fiscal 2021 First-Quarter Financial Results, Host Conference Call On Wednesday, November 4
The Pharma Data
OCTOBER 27, 2020
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. PHILADELPHIA, Pa. , 28, 2020 /PRNewswire/ — Lannett Company, Inc.
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
The Pharma Data
JULY 21, 2022
About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.
Meiji Seika Pharma Sets up a New Subsidiary in the US
The Pharma Data
JANUARY 4, 2021
Meiji Seika Pharma, since it launched penicillin in Japan in 1946, has been providing high-quality pharmaceutical products such as antibiotics, antidepressants and antipsychotics in Japan and overseas. As a “Speciality & Generic Pharmaceutical Company”, Meiji focuses its pharmaceutical business on infectious disease, central nervous system disorders, and generic drugs as well. 5, 2021 01:00 UTC.
Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA
The Pharma Data
JUNE 17, 2022
Sandoz, a global leader in generic and biosimilar medicines, today announced that the European Medicines Agency (EMA) has accepted the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz ® (adalimumab) for regulatory review.
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
The Pharma Data
JULY 25, 2022
Sandoz, a global leader in generic and biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA) for a proposed first-of-a-kind biosimilar natalizumab, developed by Polpharma Biologics. About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.
Jubilant Pharma Ltd. and Aavis Pharmaceuticals launch Hydroxychloroquine Sulfate tablets in the U.S. market
The Pharma Data
NOVEMBER 5, 2020
and Aavis Pharmaceuticals Inc. “We are pleased to announce the commercial launch of Hydroxychloroquine Sulfate tablets in the U.S.through our marketing partner,” stated Ashok Barot , Chairman, Aavis Pharmaceuticals. We’ll continue our efforts to be a significant and reliable supplier of this product,” stated Swapnil Shah , Managing Director, Senores Pharmaceuticals, R&D partner and an affiliate of Aavis Pharmaceuticals. YARDLEY, Pa.
Novartis’ Sandoz Launches Biosimilars Awareness Campaign to Improve Biosimilars Adoption Worldwide
XTalks
JUNE 8, 2022
Novartis’ biosimilars and generics drug division Sandoz has announced a new global campaign called ‘Act4Biosimilars’ to help raise awareness about biosimilars and increase their adoption by at least 30 percent in over 30 countries by the year 2030.
Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030
The Pharma Data
MAY 31, 2022
Sandoz, a global leader in generic and biosimilar medicines, today announced the launch of a new global initiative called ‘Act4Biosimilars’ to help address health inequity and inequality worldwide. Our ambition is to be the world’s leading and most valued generics company.
FDA Approves First Generic of Symbicort to Treat Asthma and COPD
The Pharma Data
MARCH 15, 2022
Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. This complex generic drug-device combination product, which is a metered-dose inhaler, should not be used to treat acute asthma attacks.
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
The Pharma Data
OCTOBER 26, 2021
Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines.
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
The Pharma Data
MAY 8, 2021
Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label.
Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF
The Pharma Data
DECEMBER 23, 2020
Aurobindo Pharma Limited (NSE: AUROPHARMA) (BSE: 524804) (Reuters: ARBN.NS) (Bloomberg: ARBP:IN), headquartered at Hyderabad, India , manufactures generic pharmaceuticals and active pharmaceutical ingredients. . HYDERABAD, India , Dec.
COVAXX and Aurobindo Pharma Announce COVID-19 Vaccine Partnership
The Pharma Data
DECEMBER 23, 2020
Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. 24, 2020 13:15 UTC. HAUPPAUGE, N.Y.–(
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
The Pharma Data
MAY 18, 2021
Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients. In line with plans announced with the Austrian government in July 2020, Sandoz confirms that in a first step it will proceed to invest more than €100 million to introduce new manufacturing technology for the production of oral amoxicillin, an active pharmaceutical ingredient (API) for its leading penicillin product.
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine | Novartis
The Pharma Data
MAY 2, 2021
Eylea ® is a trademark of Bayer AG and in the US of Regeneron Pharmaceuticals, Inc. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.
Let's personalize your content